Supporting the link between nitric oxide synthase activity and myopia progression, intravitreal administration of N-nitro-L-arginine methyl ester (L-NAME), a nitric oxide synthase inhibitor, has been shown to decelerate the progression of myopia in LIM chicks [13] and to increase NOS activity along with cyclic guanosine monophosphate (cGMP) levels in chronic form-deprivation myopia (FDM) guinea pigs [14]. The gene discussed is NOS2; the disease is myopia.